458 related articles for article (PubMed ID: 16951908)
1. Effects of parathyroid hormone alone or in combination with antiresorptive therapy on bone mineral density and fracture risk--a meta-analysis.
Vestergaard P; Jorgensen NR; Mosekilde L; Schwarz P
Osteoporos Int; 2007 Jan; 18(1):45-57. PubMed ID: 16951908
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy with parathyroid hormone analogs and antiresorptive agents for osteoporosis: a systematic review and meta-analysis of randomized controlled trials.
Lou S; Lv H; Yin P; Li Z; Tang P; Wang Y
Osteoporos Int; 2019 Jan; 30(1):59-70. PubMed ID: 30539271
[TBL] [Abstract][Full Text] [Related]
3. The Efficacy of Parathyroid Hormone Analogues in Combination With Bisphosphonates for the Treatment of Osteoporosis: A Meta-Analysis of Randomized Controlled Trials.
Li W; Chen W; Lin Y
Medicine (Baltimore); 2015 Sep; 94(38):e1156. PubMed ID: 26402797
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy of anabolic and nonbisphosphonates antiresorptive agents for the treatment of osteoporosis: A meta-analysis.
Lou S; Wang L; Wang Y; Jiang Y; Liu J; Wang Y
Medicine (Baltimore); 2017 Dec; 96(52):e9534. PubMed ID: 29384970
[TBL] [Abstract][Full Text] [Related]
5. Parathyroid hormone versus bisphosphonate treatment on bone mineral density in osteoporosis therapy: a meta-analysis of randomized controlled trials.
Shen L; Xie X; Su Y; Luo C; Zhang C; Zeng B
PLoS One; 2011; 6(10):e26267. PubMed ID: 22022584
[TBL] [Abstract][Full Text] [Related]
6. Full length parathyroid hormone, PTH(1-84), for the treatment of severe osteoporosis in postmenopausal women.
Adami S
Curr Med Res Opin; 2008 Nov; 24(11):3259-74. PubMed ID: 18940041
[TBL] [Abstract][Full Text] [Related]
7. Treatment of postmenopausal women with osteoporosis with PTH(1-84) for 36 months: treatment extension study.
Zanchetta JR; Bogado CE; Cisari C; Aslanidis S; Greisen H; Fox J; Lems W
Curr Med Res Opin; 2010 Nov; 26(11):2627-33. PubMed ID: 20923256
[TBL] [Abstract][Full Text] [Related]
8. Effects of increasing age, dosage, and duration of PTH treatment on BMD increase--a meta-analysis.
Schwarz P; Jorgensen NR; Mosekilde L; Vestergaard P
Calcif Tissue Int; 2012 Mar; 90(3):165-73. PubMed ID: 22237954
[TBL] [Abstract][Full Text] [Related]
9. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial.
Greenspan SL; Bone HG; Ettinger MP; Hanley DA; Lindsay R; Zanchetta JR; Blosch CM; Mathisen AL; Morris SA; Marriott TB;
Ann Intern Med; 2007 Mar; 146(5):326-39. PubMed ID: 17339618
[TBL] [Abstract][Full Text] [Related]
10. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis.
Hodsman AB; Fraher LJ; Watson PH; Ostbye T; Stitt LW; Adachi JD; Taves DH; Drost D
J Clin Endocrinol Metab; 1997 Feb; 82(2):620-8. PubMed ID: 9024265
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of osteoporosis with parathyroid hormone].
Syversen U; Halse JI
Tidsskr Nor Laegeforen; 2008 Jan; 128(1):39-41. PubMed ID: 18183056
[TBL] [Abstract][Full Text] [Related]
12. [Anabolic treatment for osteoporosis: PTH treatment].
Kaji H; Sugimoto T
Clin Calcium; 2006 Sep; 16(9):1480-85. PubMed ID: 16951472
[TBL] [Abstract][Full Text] [Related]
13. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal.
Cosman F; Nieves J; Woelfert L; Formica C; Gordon S; Shen V; Lindsay R
J Bone Miner Res; 2001 May; 16(5):925-31. PubMed ID: 11341338
[TBL] [Abstract][Full Text] [Related]
14. Combination of anabolic and antiresorptive agents for the treatment of osteoporosis.
Garcés C; García LE
Maturitas; 2006 Apr; 54(1):47-54. PubMed ID: 16257150
[TBL] [Abstract][Full Text] [Related]
15. Parathyroid Hormone Plus Alendronate in Osteoporosis: A Meta-Analysis of Randomized Controlled Trials.
Wang C; Zhang G; Gu M; Fan J; Chen J; Zhang G; Li B
J Invest Surg; 2015; 28(6):309-16. PubMed ID: 26270229
[TBL] [Abstract][Full Text] [Related]
16. [Parathyroid and bone. Evidence and perspective of parathyroid therapy for patients with osteoporosis].
Wada S; Fukawa T; Kamiya S
Clin Calcium; 2007 Dec; 17(12):1888-94. PubMed ID: 18057665
[TBL] [Abstract][Full Text] [Related]
17. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents.
Hochberg MC; Greenspan S; Wasnich RD; Miller P; Thompson DE; Ross PD
J Clin Endocrinol Metab; 2002 Apr; 87(4):1586-92. PubMed ID: 11932287
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of bisphosphonates against osteoporosis in adult men: a meta-analysis of randomized controlled trials.
Chen L; Wang G; Zheng F; Zhao H; Li H
Osteoporos Int; 2015 Sep; 26(9):2355-63. PubMed ID: 25944731
[TBL] [Abstract][Full Text] [Related]
19. Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis: meta-analysis of randomised controlled trials.
Han SL; Wan SL
Int J Clin Pract; 2012 Feb; 66(2):199-209. PubMed ID: 22257045
[TBL] [Abstract][Full Text] [Related]
20. New therapeutic targets for osteoporosis.
Anagnostis P; Gkekas NK; Potoupnis M; Kenanidis E; Tsiridis E; Goulis DG
Maturitas; 2019 Feb; 120():1-6. PubMed ID: 30583758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
